Evidence map›Paper›PMID 22531326›Full record

ReviewNature reviews. Immunology2012

Multipotent mesenchymal stromal cells and the innate immune system.

Katarina Le Blanc, Dimitrios Mougiakakos

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02325843 (The Subconjunctival Injection of Human Bone Marrow Mesenchymal Stem Cells for Ocular Corneal Burn), which is not on this map. Cited by 533 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
533citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02325843 phase2completednot on this mapstarted 2015, after this paper: background citation

The Subconjunctival Injection of Human Bone Marrow Mesenchymal Stem Cells for Ocular Corneal Burn: Prospective, Case Series Study

TypeinterventionalSponsorSun Yat-sen UniversityRan2015 to 2017Enrolled16ConditionsChemical BurnsArmshuman bone marrow MSC
3 · Its place in the literature

Who cites it

533 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

473 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Katarina Le BlancDepartment of Medicine, Karolinska Institutet, Haematology Centre, Karolinska University Hospital, Stockholm, Sweden. katarina.leblanc@ki.se
Dimitrios Mougiakakos

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multipotent mesenchymal stromal cells (MSCs) have unique immunoregulatory and regenerative properties that make them an attractive tool for the cellular treatment of autoimmunity and inflammation. Their underlying molecular mechanisms of action together with their clinical benefit - for example, in autoimmunity - are being revealed by an increasing number of clinical trials and preclinical studies of MSCs. However, autoimmunity and therapy-related alloimmunity are not only triggered and sustained by responses of the adaptive immune system; there is growing evidence that components of the innate immune system also have a key role. It is therefore important to study the crosstalk between MSCs and innate immunity, which ranges from the bone marrow niche to injured tissue.

Indexed as

Immunity, InnateBone Marrow CellsHumansMesenchymal Stem Cells

Identifiers

PMID22531326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.